{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"8.0","value":"5.0"},{"groupId":"OG001","lowerLimit":"2.7","upperLimit":"8.0","value":"8.0"},{"groupId":"OG002","lowerLimit":"4.0","upperLimit":"8.0","value":"6.0"},{"groupId":"OG003","lowerLimit":"4.0","upperLimit":"8.0","value":"6.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"description":"Tmax is the the time at which the maximum plasma concentration (Cmax) is observed.","dispersionType":"Full Range","groups":[{"description":"Participants who received a 300 mg dose of venetoclax administered on the intensive pharmacokinetic sampling day","id":"OG000","title":"300 mg Venetoclax"},{"description":"Participants who received a 600 mg dose of venetoclax administered on the intensive pharmacokinetic sampling day","id":"OG001","title":"600 mg Venetoclax"},{"description":"Participants who received a 900 mg dose of venetoclax administered on the intensive pharmacokinetic sampling day","id":"OG002","title":"900 mg Venetoclax"},{"description":"Participants who received a 1200 mg dose of venetoclax administered on the intensive pharmacokinetic sampling day","id":"OG003","title":"1200 mg Venetoclax"}],"paramType":"MEDIAN","populationDescription":"Phase 1 dose escalation and safety expansion participants with available data","reportingStatus":"POSTED","timeFrame":"Cycle 2, Day 1 at predose, 2, 4, 6, 8, and 24 hours postdose","title":"Phase 1: Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax","type":"PRIMARY","unitOfMeasure":"hours"}